For in vitro diagnostic use. Others Elecsys CA 19-9 IVD Elecsys® CA 19-9 CPS_000449 07 027 028 190 7 027 028 190 07027028190 7027028190 07027028190 CA 19-9 Elecsys E2G 300 Elecsys CA 19-9 04015630939640 Reagents, kits 300 tests cobas e 402/801 true 11 776 193 122 11776193122 CA 19-9 Elecsys cobas e 100 Elecsys CA 19-9 04015630904297 Reagents, kits 100 tests cobas e 411/601/602 true 07 027 028 214 7 027 028 214 07027028214 7027028214 07027028214 CA 19-9 Elecsys E2G 300 Elecsys CA 19-9 07613336194102 Reagents, kits 300 tests cobas e 402/801 true 11 776 193 214 11776193214 CA 19-9 Elecsys cobas e 100 Elecsys CA 19-9 07613336162866 Reagents, kits 100 tests cobas e 411/601/602 true 07027028501 Elecsys CA 19-9 en 2 FF000000041A4E0E FF00000001C48E0E 07027028190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of CA 19‑9 tumor associated antigen, in human serum and plasma. The assay is indicated for the serial measurement of CA 19‑9 to aid in the management of patients diagnosed with cancers of the exocrine pancreas. The test is useful as an aid in the monitoring of disease status in those patients having confirmed pancreatic cancer who have levels of CA 19‑9 at some point in their disease process exceeding the median concentration determined for the apparently healthy cohort.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 07027028500 Elecsys CA 19-9 en 8 FF00000006AF0F0E FF000000045D600E 07027028190 07027028214 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of CA 19‑9 in human serum and plasma.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 07027028501 Elecsys CA 19-9 en 3 FF00000006C8570E FF000000041A4E0E 07027028190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of CA 19‑9 tumor associated antigen, in human serum and plasma. The assay is indicated for the serial measurement of CA 19‑9 to aid in the management of patients diagnosed with cancers of the exocrine pancreas. The test is useful as an aid in the monitoring of disease status in those patients having confirmed pancreatic cancer who have levels of CA 19‑9 at some point in their disease process exceeding the median concentration determined for the apparently healthy cohort.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 07027028501 Elecsys CA 19-9 en 1 FF00000001E7300E FF00000001E7300E 07027028190 2497 cobas e 801 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of CA 19‑9 tumor associated antigen, in human serum and plasma. The assay is indicated for the serial measurement of CA 19‑9 to aid in the management of patients diagnosed with cancers of the exocrine pancreas. The test is useful as an aid in the monitoring of disease status in those patients having confirmed pancreatic cancer who have levels of CA 19‑9 at some point in their disease process exceeding the median concentration determined for the apparently healthy cohort.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 07027028500 Elecsys CA 19-9 en 5 FF000000043B790E FF00000001711D0E 07027028190 2497 cobas e 801 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of CA 19‑9 in human serum and plasma.The electrochemiluminescence immunoassay “ECLIA” is intended for use on the cobas e 801 immunoassay analyzer. en 11776193501 Elecsys CA 19-9 en 9 FF000000041A470E FF00000000728F0E 11776193122 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of CA 19‑9 tumor associated antigen, in human serum and plasma. The assay is indicated for the serial measurement of CA 19‑9 to aid in the management of patients diagnosed with cancers of the exocrine pancreas. The test is useful as an aid in the monitoring of disease status in those patients having confirmed pancreatic cancer who have levels of CA 19‑9 at some point in their disease process exceeding the median concentration determined for the apparently healthy cohort.The electrochemiluminescence immunoassay “ECLIA” is intended for use on Elecsys and cobas e immunoassay analyzers. en 11776193500 Elecsys CA 19-9 en 24 FF0000000403330E FF0000000032CB0E 11776193122 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of CA 19‑9 in human serum and plasma.The electrochemiluminescence immunoassay “ECLIA” is intended for use on Elecsys and cobas e immunoassay analyzers. en

User Profile

Select your user profile

Elecsys^® CA 19-9

Overview

Ordering Information

Technical Documents

Access important product documentation including relevant certificates and other resources.

Compatible products

Related products

Contact us